Our results, which combined diverse cell lines with tumoroids and in vivo models of KRAS-mutant cancers, suggest that Mediator kinase inhibitors may be broadly effective in blocking short- and long-term transcriptional changes required for the emergence of drug resistant cell populations. Here, KRAS is linked to cancer.